Digital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Your Basket's Financial Footprint
Summary of total market capitalisation and constituent breakdown for the Digital Therapeutics & Prescription Apps basket.
- Large-cap dominance implies generally lower volatility and more stable, market-tracking performance compared with smaller-cap-focused baskets.
- Suitable as a core holding: adds broad sector exposure, not recommended as a speculative, short-term trade.
- Expect steady, long-term value; unlikely to deliver rapid, explosive short-term gains.
DRIO: $51.25M
GDRX: $1.35B
TDOC: $1.53B
- Other
About This Group of Stocks
Our Expert Thinking
Digital therapeutics represent a fundamental shift in healthcare delivery. These clinically-validated software programs are designed to prevent, manage, or treat medical conditions without traditional drugs or devices. As healthcare embraces technology, these scalable solutions promise better patient outcomes at lower costs.
What You Need to Know
This is an emerging, high-growth sector with significant potential but also substantial risk. Insurance reimbursement is the critical catalyst for widespread adoption. Companies range from pure-play digital therapeutics developers to larger telehealth platforms incorporating these technologies into broader offerings.
Why These Stocks
We've selected companies directly involved in creating or delivering software-based medical treatments. This includes dedicated digital therapeutics developers, telehealth platforms enabling digital prescriptions, and companies creating complementary technologies that support this emerging ecosystem.
Why You'll Want to Watch These Stocks
Software Is Becoming Medicine
These companies are creating FDA-cleared apps that actually treat diseases. It's a whole new category of medicine where code itself becomes the treatment—potentially reaching millions of patients at a fraction of traditional costs.
Insurance Companies Are Paying Up
The big breakthrough? Insurance providers are increasingly willing to reimburse for these digital therapies. This payment validation could trigger explosive growth as these treatments become mainstream healthcare options.
Early Days of a Healthcare Revolution
We're just at the beginning of software-as-medicine. With chronic diseases, mental health conditions, and preventative care all being targeted, these companies are pioneering what could become a multi-billion dollar healthcare category.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Digital Trust Stocks | Cybersecurity Investment Opportunity
Fifteen global tech giants, led by Microsoft and Ericsson, have formed an alliance to establish a common framework for digital trust and security. This move signals a growing demand for specialized cybersecurity and verification technologies, creating an investment opportunity in companies that provide the essential tools for a trusted digital ecosystem.
Food Safety Stocks: What's Next After Costco Lawsuit
A recent lawsuit against Costco regarding salmonella in its rotisserie chicken has intensified focus on food safety across the grocery industry. This creates a potential investment opportunity in companies that provide testing, diagnostics, and supply chain verification services.
Founder-Controlled Stocks May Gain Focus in 2025
SpaceX is reportedly considering a dual-class share structure for its IPO to ensure founder Elon Musk retains control. This move could spark investor interest in other public companies where founders or insiders hold significant voting power through similar stock structures.